Literature DB >> 22350917

PROTAC-induced proteolytic targeting.

Kimberly Cornish Carmony1, Kyung-Bo Kim.   

Abstract

Small-molecule modulators of protein activity are increasingly being utilized as tools to examine the functional roles of proteins. Operating at the post-translational level, these molecules provide enhanced temporal and spatial control and mitigate the potential for compensatory responses in comparison with classical genetic approaches. Proteolysis targeting chimeric molecules, or PROTACs, are small molecules that inhibit the function of their target proteins by targeting them for degradation by the ubiquitin proteasome system. This chapter summarizes strategies for PROTAC preparation and characterization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350917      PMCID: PMC3852687          DOI: 10.1007/978-1-61779-474-2_44

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  19 in total

1.  Impact of linker length on the activity of PROTACs.

Authors:  Kedra Cyrus; Marie Wehenkel; Eun-Young Choi; Hyeong-Jun Han; Hyosung Lee; Hollie Swanson; Kyung-Bo Kim
Journal:  Mol Biosyst       Date:  2010-10-04

2.  Degradation of target protein in living cells by small-molecule proteolysis inducer.

Authors:  Dong Zhang; Sun Hee Baek; Abby Ho; Kyungbo Kim
Journal:  Bioorg Med Chem Lett       Date:  2004-02-09       Impact factor: 2.823

3.  Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

Authors:  A Rodriguez-Gonzalez; K Cyrus; M Salcius; K Kim; C M Crews; R J Deshaies; K M Sakamoto
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

4.  Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

Authors:  Yukihiro Itoh; Minoru Ishikawa; Mikihiko Naito; Yuichi Hashimoto
Journal:  J Am Chem Soc       Date:  2010-04-28       Impact factor: 15.419

5.  Chimeric molecules to target proteins for ubiquitination and degradation.

Authors:  Kathleen M Sakamoto
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 6.  Protacs for treatment of cancer.

Authors:  Kathleen M Sakamoto
Journal:  Pediatr Res       Date:  2010-05       Impact factor: 3.756

7.  Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

Authors:  Masaya Baba; Syuiohi Hirai; Hisafumi Yamada-Okabe; Kenji Hamada; Hisahiro Tabuchi; Kazuki Kobayashi; Keiichi Kondo; Minoru Yoshida; Akio Yamashita; Takeshi Kishida; Noboru Nakaigawa; Youji Nagashima; Yoshinobu Kubota; Masahiro Yao; Shigeo Ohno
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

8.  Chemical genetic control of protein levels: selective in vivo targeted degradation.

Authors:  John S Schneekloth; Fabiana N Fonseca; Michael Koldobskiy; Amit Mandal; Raymond Deshaies; Kathleen Sakamoto; Craig M Crews
Journal:  J Am Chem Soc       Date:  2004-03-31       Impact factor: 15.419

9.  Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.

Authors:  Kathleen M Sakamoto; Kyung B Kim; Rati Verma; Andy Ransick; Bernd Stein; Craig M Crews; Raymond J Deshaies
Journal:  Mol Cell Proteomics       Date:  2003-10-02       Impact factor: 5.911

10.  Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling.

Authors:  Wei Li; Mario H Bengtson; Axel Ulbrich; Akio Matsuda; Venkateshwar A Reddy; Anthony Orth; Sumit K Chanda; Serge Batalov; Claudio A P Joazeiro
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

View more
  5 in total

Review 1.  Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs.

Authors:  Mohd Muddassir; Kunjal Soni; Chetan B Sangani; Abdullah Alarifi; Mohd Afzal; Naaser A Y Abduh; Yongtao Duan; Poonam Bhadja
Journal:  RSC Adv       Date:  2020-12-24       Impact factor: 4.036

2.  Ubiquitin-independent, Proteasome-mediated targeted degradation of KRAS in pancreatic adenocarcinoma cells using an engineered ornithine decarboxylase/antizyme system.

Authors:  Yihui Ma; Jingjing Xu; Pei Huang; Xue Bai; Hanqing Gao
Journal:  IUBMB Life       Date:  2018-10-22       Impact factor: 3.885

3.  Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.

Authors:  C Otto; S Schmidt; C Kastner; S Denk; J Kettler; N Müller; C T Germer; E Wolf; P Gallant; A Wiegering
Journal:  Neoplasia       Date:  2019-11-14       Impact factor: 5.715

Review 4.  The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases.

Authors:  Verena Katharina Raker; Christian Becker; Kerstin Steinbrink
Journal:  Front Immunol       Date:  2016-03-31       Impact factor: 7.561

5.  BET degrader inhibits tumor progression and stem-like cell growth via Wnt/β-catenin signaling repression in glioma cells.

Authors:  Tao Tian; Tongqi Guo; Wei Zhen; Jianjun Zou; Fuyong Li
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.